Healthcare · Biotechnology
Price
$1.03
Market Cap
$12.2M
Employees
43
Beta
-0.04
Avg Volume
17,175
CEO
Chee Kong Choo
Business Description
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Business History
Price Overview
Last updated: Jun 27, 2026 10:07am (just now)$1.02
+0.03 (+3.03%)
Day Range
$1.02 – $1.11
52-Week Range
$0.68 – $3.68
50-Day MA
$1.05
200-Day MA
$1.40
Volume
57,033.00
Share Structure
Outstanding
11,832,835.00
Float
3,912,728.00
Free Float
33.1%
Moderate free float
— 33.1% of shares trade freely, ~66.9% held by insiders/institutions
Reasonable but insiders still hold a significant stake. This can be positive (skin in the game) but may limit liquidity during sell-offs.
Small absolute float (3.9M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-3.12
Stock Price: $1.03
EPS (Diluted): -0.33
EPS (Diluted): -0.33
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.07
Stock Price: $1.03
Total Equity: $6.54M
Shares: 11,647,225
Total Equity: $6.54M
Shares: 11,647,225
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-2.84
Market Cap: $12.19M
Total Debt: $409,503
Cash: $2.10M
EBITDA: -$4.30M
Total Debt: $409,503
Cash: $2.10M
EBITDA: -$4.30M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$18.5M
Market Cap: $12.19M
Total Debt: $409,503
Cash: $2.10M
Total Debt: $409,503
Cash: $2.10M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
62.86
Stock Price: $1.03
Revenue: $319,201
Shares: 11,647,225
Revenue: $319,201
Shares: 11,647,225
EV/Sales (Total value vs revenue — works when P/E can't)
API57.81
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
-277.7%
Gross Profit: -$886,564
Revenue: $319,201
Revenue: $319,201
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-1,416.0%
Operating Income: -$4.52M
Revenue: $319,201
Revenue: $319,201
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-1,227.1%
Net Income: -$3.92M
Revenue: $319,201
Revenue: $319,201
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-73.1%
Net Income: -$3.92M
Total Equity: $6.54M
Total Equity: $6.54M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-72.8%
Operating Income: -$4.52M
Tax Rate: 0.0%
Equity: $6.54M
Total Debt: $409,503
Cash: $2.10M
Tax Rate: 0.0%
Equity: $6.54M
Total Debt: $409,503
Cash: $2.10M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
5.17
Current Assets: $3.66M
Current Liabilities: $709,169
Current Liabilities: $709,169
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.06
Short-Term Debt: $40,847
Long-Term Debt: $368,656
Total Debt: $409,503
Total Equity: $6.54M
Long-Term Debt: $368,656
Total Debt: $409,503
Total Equity: $6.54M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.03
Revenue: $319,201
Shares: 11,647,225
Shares: 11,647,225
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.56
Total Equity: $6.54M
Shares: 11,647,225
Shares: 11,647,225
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.38
Operating CF: -$3.70M
CapEx: -$703,134
Shares: 11,647,225
CapEx: -$703,134
Shares: 11,647,225
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.03
Stock Price: $1.03
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$3.92M
Net Income: -$3.92M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares GDTC against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 23, 2026 3:41pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $365,604 | $509,125 | $69,501 | $319,201 |
| Cost of Revenue | $3,501 | $109,042 | $3,736 | $17,121 | $1.2M |
| Gross Profit | $110,291 | $-109,042 | $505,387 | $52,380 | $-886,564 |
| Operating Expenses | $1.3M | $2.2M | $2.1M | $3.2M | $3.6M |
| Operating Income | -$1.2M | -$2.3M | -$1.6M | -$3.1M | -$4.5M |
| Net Income | -$2.1M | -$3.1M | -$4.1M | -$2.6M | -$3.9M |
| EBITDA | -$1.4M | -$1.5M | -$3.9M | -$2.4M | -$4.3M |
| EPS | $-0.30 | $-0.40 | $-0.38 | $-0.22 | $-0.33 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 3:41pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.5M | $1.6M | $9.0M | $5.0M | $2.1M |
| Total Current Assets | $3.3M | $2.5M | $10.1M | $6.0M | $3.7M |
| Total Assets | $6.1M | $5.3M | $12.4M | $10.1M | $8.0M |
| Current Liabilities | $2.9M | $4.2M | $718,905 | $606,487 | $709,169 |
| Long-Term Debt | $540,379 | $471,008 | $408,887 | $394,222 | $368,656 |
| Total Liabilities | $3.5M | $4.7M | $1.1M | $1.0M | $1.1M |
| Total Equity | $2.6M | $589,712 | $11.3M | $9.0M | $6.5M |
| Retained Earnings | -$5.1M | -$8.2M | -$12.4M | -$14.8M | -$18.8M |
Cash Flow (Annual)
Last updated: Jun 23, 2026 3:41pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$1.7M | -$1.4M | -$3.5M | -$2.7M | -$3.7M |
| Capital Expenditure | $-583,715 | $-475,999 | $-58,454 | -$1.4M | $-703,134 |
| Free Cash Flow | -$2.3M | -$1.9M | -$3.6M | -$4.1M | -$4.4M |
| Acquisitions (net) | $0 | $478 | $0 | $0 | $1.2M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $1.6M | $-920,041 | $4.7M | -$1.7M | -$2.6M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 11:17am (22h ago)| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue |
$520,000 $520,000 – $520,000
|
$779,649 $779,649 – $779,649
|
$668,569 $668,569 – $668,569
|
| EBITDA |
$-312,000 $-312,000 – $-312,000
|
$-467,789 $-467,789 – $-467,789
|
$-401,141 $-401,141 – $-401,141
|
| Net Income |
-$3.0M -$3.0M – -$3.0M
|
-$2.4M -$2.4M – -$2.4M
|
-$2.5M -$2.5M – -$2.5M
|
| EPS | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 3:41pm (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | +39.3% | -86.3% | +359.3% |
| Gross Profit Growth | -198.9% | +563.5% | -89.6% | -1,792.6% |
| Operating Income Growth | -97.5% | +30.8% | -98.2% | -44.4% |
| Net Income Growth | -47.3% | -35.6% | +38.0% | -52.3% |
| EBITDA Growth | -4.0% | -163.8% | +37.1% | -75.7% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 8:44am (1h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-13 | Choo Chee Kong | P-Purchase | 112,000.00 | $1.15 | $128,778 |
| 2026-03-18 | Toh Keng Kiat | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Yew Chak Hua | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Leong Mark Kei Wei | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Choo Chee Kong | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Choo Chee Kong | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Choo Chee Kong | 0.00 | $0.00 | $0 | |
| 2026-03-18 | TAN YOONG YING | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Goh Yvonne | 0.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for GDTC — it's generated by the pipeline (
market-narrative step).
No community reviews yet for GDTC.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30